Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair

Chemotherapy is the only choice for most of the advanced hepatocellular carcinoma (HCC) patients, while few agents were available, making it an urgent need to develop new chemotherapy strategies. A phase II clinical trial suggested that the efficacy of irinotecan in HCC was limited due to dose-depen...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Jinjin, Xu, Zhifei, Peng, Xueming, Chen, Min, Zhu, Yuanrun, Xu, Li, Zhu, Hong, Yang, Bo, Luo, Peihua, He, Qiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709237/
https://www.ncbi.nlm.nih.gov/pubmed/26752698
http://dx.doi.org/10.1371/journal.pone.0146968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709237/
https://www.ncbi.nlm.nih.gov/pubmed/26752698
http://dx.doi.org/10.1371/journal.pone.0146968

Ejemplares similares